Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. Materials and methods: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. Results: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. Conclusions: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalRadiotherapy and Oncology
Volume127
Issue number1
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Propensity Score
Glioblastoma
Radiotherapy
Adjuvant Chemotherapy

Keywords

  • Glioblastoma
  • Propensity score matching
  • Radiation therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{f59ec4e6ee864db9ad111dead8f702b1,
title = "Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis",
abstract = "Background: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. Materials and methods: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. Results: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6{\%}, 32.7{\%}, and 15.5{\%} for the CRT-group, and 75.6{\%}, 33.3{\%}, and 18.9{\%} for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. Conclusions: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.",
keywords = "Glioblastoma, Propensity score matching, Radiation therapy",
author = "Pierina Navarria and Federico Pessina and Ciro Franzese and Stefano Tomatis and Matteo Perrino and Luca Cozzi and Matteo Simonelli and Lorenzo Bello and Elena Clerici and Marco Riva and Armando Santoro and Marta Scorsetti",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.radonc.2017.12.006",
language = "English",
volume = "127",
pages = "108--113",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis

AU - Navarria, Pierina

AU - Pessina, Federico

AU - Franzese, Ciro

AU - Tomatis, Stefano

AU - Perrino, Matteo

AU - Cozzi, Luca

AU - Simonelli, Matteo

AU - Bello, Lorenzo

AU - Clerici, Elena

AU - Riva, Marco

AU - Santoro, Armando

AU - Scorsetti, Marta

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. Materials and methods: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. Results: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. Conclusions: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.

AB - Background: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. Materials and methods: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. Results: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. Conclusions: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.

KW - Glioblastoma

KW - Propensity score matching

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85039551401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039551401&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2017.12.006

DO - 10.1016/j.radonc.2017.12.006

M3 - Article

C2 - 29291951

AN - SCOPUS:85039551401

VL - 127

SP - 108

EP - 113

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -